Free Trial
NASDAQ:APRE

Aprea Therapeutics Q3 2023 Earnings Report

Aprea Therapeutics logo
$1.74 -0.06 (-3.33%)
As of 05/30/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aprea Therapeutics EPS Results

Actual EPS
-$0.86
Consensus EPS
-$1.08
Beat/Miss
Beat by +$0.22
One Year Ago EPS
N/A

Aprea Therapeutics Revenue Results

Actual Revenue
$0.32 million
Expected Revenue
$0.25 million
Beat/Miss
Beat by +$70.00 thousand
YoY Revenue Growth
N/A

Aprea Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
11:00AM ET

Upcoming Earnings

Aprea Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aprea Therapeutics Earnings Headlines

This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

View Aprea Therapeutics Profile

More Earnings Resources from MarketBeat